Ser130
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.9
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser130  -  PXN (human)

Site Information
kQksAEPsPtVMsts   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 450228

In vivo Characterization
Methods used to characterize site in vivo:
electrophoretic mobility shift ( 10 ) , mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 7 , 8 , 11 , 12 , 13 , 14 , 15 , 16 ) , mutation of modification site ( 6 , 10 ) , western blotting ( 10 )
Disease tissue studied:
breast cancer ( 3 , 5 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 ) , leukemia ( 10 ) , chronic lymphocytic leukemia ( 10 ) , lung cancer ( 6 , 8 , 14 , 15 ) , non-small cell lung cancer ( 6 , 8 , 14 , 15 ) , non-small cell lung adenocarcinoma ( 6 , 14 )
Relevant cell line - cell type - tissue:
A498 (renal) ( 12 ) , A549 (pulmonary) ( 6 , 14 ) , AB.1 (T lymphocyte) ( 10 ) , breast ( 1 ) , BT-474 (breast cell) ( 3 ) , Calu 6 (pulmonary) ( 8 ) , H2077 (pulmonary) ( 8 ) , H322M (pulmonary) ( 8 ) , HCC1359 (pulmonary) ( 8 ) , HCC4006 (pulmonary) ( 8 ) , HeLa (cervical) ( 4 , 6 , 16 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 5 ) , HMLER ('stem, breast cancer') ( 5 ) , HUES-9 ('stem, embryonic') ( 11 ) , K562 (erythroid) ( 7 , 13 ) , L1210 (lymphoblast) ( 10 ) , LOU-NH91 (squamous) ( 8 ) , MCF-7 (breast cell) ( 2 , 3 ) , NCI-H1395 (pulmonary) ( 8 ) , NCI-H1648 (pulmonary) ( 8 ) , NCI-H2030 (pulmonary) ( 8 ) , NCI-H3255 (pulmonary) ( 15 ) , NCI-H460 (pulmonary) ( 8 )

Upstream Regulation
Treatments:
antibody ( 10 ) , dasatinib ( 13 ) , U0126 ( 10 )

Downstream Regulation
Effects of modification on biological processes:
cell motility, induced ( 6 ) , cytoskeletal reorganization ( 6 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Sacco F, et al. (2016) Deep Proteomics of Breast Cancer Cells Reveals that Metformin Rewires Signaling Networks Away from a Pro-growth State. Cell Syst 2, 159-71
27135362   Curated Info

3

Carrier M, et al. (2016) Phosphoproteome and Transcriptome of RA-Responsive and RA-Resistant Breast Cancer Cell Lines. PLoS One 11, e0157290
27362937   Curated Info

4

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

5

Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90
24782546   Curated Info

6

Radtke S, et al. (2013) ERK2 but not ERK1 mediates HGF-induced motility in non-small cell lung carcinoma cell lines. J Cell Sci 126, 2381-91
23549785   Curated Info

7

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

8

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

9

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

10

Robertson LK, Ostergaard HL (2011) Paxillin Associates with the Microtubule Cytoskeleton and the Immunological Synapse of CTL through Its Leucine-Aspartic Acid Domains and Contributes to Microtubule Organizing Center Reorientation. J Immunol 187, 5824-33
22043013   Curated Info

11

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

12

Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62
20071362   Curated Info

13

Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808
19651622   Curated Info

14

Moritz A (2009) CST Curation Set: 7288; Year: 2009; Biosample/Treatment: cell line, A549/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

15

Moritz A (2009) CST Curation Set: 7286; Year: 2009; Biosample/Treatment: cell line, NCI-H3255/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

16

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2024 Cell Signaling Technology, Inc.